For nearly 50 years, the AAAS Science & Technology Policy Fellowships (STPF) have been the premier opportunity for outstanding scientists and engineers to learn first-hand about policymaking while contributing their expertise to the federal government.
What does a half century of science policy impact look like? We’re dedicating our first live chat in this six-part series for you to find out! Join us on May 27 at 2 p.m. ET for "Reflecting on Nearly 50 Years of Impact."
- Learn how fellows have been impacting science policy since the fellowship’s inception.
- Recap findings from an in-depth, independent evaluation of the STPF program.
- Hear a discussion on the current state of science policy, and the role STPF fellows will play in the future of science policy.
- Plus, you’ll have the opportunity to ask fellows your questions about the chat theme.
View the full chat schedule here.
Jessica Soule, STPF Project Director, Recruitment, Marketing & Alumni Engagement
Diana Pankevich, Ph.D., 2014-16 Executive Branch Fellow, White House Office of Science and Technology Policy
Diana serves as a Director for Science & Innovation Policy at Pfizer where she leads policy development for issues related to clinical trials, including enrollment, diversity, and data sharing. Diana also serves as the policy lead for issues related to patient centricity, oncology, digital health, expanded access, and supply chains. Diana's primary interest is in the development and implementation of evidence-based science- and health-related policies.
Previously, Diana worked at the White House Office of Science and Technology Policy (OSTP) where she supported the President Obama's Council of Advisors on Science and Technology (PCAST). As part of the executive secretariat for PCAST, Diana worked on a range of topics including private sector adaptation to climate change, forensic science, technology for aging, and ensuring the safety of the Nation's drinking water.
Prior to OSTP, Diana was a program officer on the Board on Health Sciences Policy at the Institute of Medicine where she staffed the Forum on Neuroscience and Nervous System Disorders. There she focused on a variety of issues including mental health care in sub-Saharan Africa and accelerating development of therapeutics for nervous system disorders.
Paul Lartey, Ph.D., 2017-19 Executive Branch Fellow, National Science Foundation, Office of Legislative and Public Affairs
Dr. Paul Lartey is CEO of LaGray, Inc., a pharmaceutical consulting company focused on improving access to medicines, especially in Africa. He is also Independent Consultant | Pharmaceutical Industry Best Practice Advisor for the National Coordination Center. Lartey is founder and was CEO of LaGray Chemical Company, Ghana, the first vertically integrated pharmaceutical research and manufacturing company in Sub-Saharan Africa. LaGray Chemical Company was the first with technology for active pharmaceutical ingredient manufacturing in West Africa.
Earlier in his career, Lartey was Director of Infectious Diseases Drug Discovery Research at Abbott Laboratories, Pharmacia & Upjohn and later Pfizer. As director of research, he led several multidisciplinary programs to successfully deliver antibacterial, antifungal and GI drug candidates. This includes the first clinically approved drug of the then novel oxazolidinone class of antibacterials.
Lartey was founding Chair of the Federation of African Pharmaceutical Manufacturers Associations. As Chair, he advocated for policies to support pharmaceutical research and manufacturing in Africa. This contributed to the development of a package of policies called the Pharmaceutical Manufacturing Plan for Africa, which was adopted and implemented by Heads of State of the African Union.
Lartey recently completed a 2-year term in the Office of the Director, National Science Foundation, as a AAAS Science & Technology Policy Fellow. At NSF, he researched and published history of global health impacts from NSF-supported basic research. In that quest, he highlighted fundamental discoveries that eventually led to diagnostic and therapeutic tools for stemming infectious disease outbreaks and preventing pandemics.
Lartey has a Bachelor’s degree in Pharmacy and a Masters in Pharmaceutical Chemistry from the University of Science and Technology, Kumasi, Ghana. His PhD is in medicinal chemistry from the State University of New York at Buffalo and post-doctoral training in synthetic organic chemistry at Yale University. He has a number of publications, abstracts and patents in drug discovery, medicinal chemistry, microbiology, pharmacology, synthetic organic chemistry and pharmaceutical policy.
Georgia Hartman, Ph.D., 2020-22 Executive Branch Fellow, US Agency for International Development, Gender Equality and Women's Empowerment Hub
Dr. Hartman holds a Ph.D. in Anthropology from the University of California, Irvine. Her research examines how the shift from state-directed to market-oriented economic reforms is reshaping the meaning of land, home, and property in Cancún, Mexico. In particular, she is interested in how mortgage finance (and credit/debt generally) shape urban space, social class, and gendered responsibilities associated with the household in Mexico. As an economic anthropologist, she specializes in examining economic exchanges as fundamentally social entanglements that shape not only our material lives, but our relationships with our families, our communities, and the societies we live in. She also holds an M.A. in Latin American Studies from the University of California, San Diego where her research examined the impact of the 2008 economic crisis on the migration decisions of a transnational migrant community in Los Angeles and Yucatán, Mexico.